Literature DB >> 24390192

Epidemiology of dural arteriovenous fistula in Japan: Analysis of Japanese Registry of Neuroendovascular Therapy (JR-NET2).

Masafumi Hiramatsu1, Kenji Sugiu, Tomohito Hishikawa, Jun Haruma, Koji Tokunaga, Isao Date, Naoya Kuwayama, Nobuyuki Sakai.   

Abstract

We developed the Japanese Registry of Neuroendovascular Therapy 2 (JR-NET2) database and used the information for a retrospective, nation-wide multicenter, observational study to clarify the clinical characteristics, current status of procedures, and outcome of patients treated by neuroendovascular therapy in Japan. In this report, we analyzed the clinical characteristics of dural arteriovenous fistulas (dAVFs) in the JR-NET2 database. All patients with dAVFs treated with endovascular therapy in 150 Japanese hospitals were included. Patient characteristics, clinical presentations, and imaging characteristics were analyzed. A total of 1,075 patients with dAVFs underwent 1,520 endovascular procedures. Of 1,075 patients, 45% were men and 55% were women. The mean age was 65 ± 13 years. The most frequent location of dAVFs was the cavernous sinus (43.6%), followed by the transverse-sigmoid sinus (TSS) (33.4%). Twelve percent of the patients had intracranial hemorrhage, 9% had venous infarction, and 3% had convulsion. The statistically significant independent risk factors of intracranial hemorrhage were TSS, superior sagittal sinus (SSS), tentorium, anterior cranial fossa, cranio-cervical junction, cortical venous reflux (CVR), and varix. Risk factors of venous infarction were age older than 60 years, male sex, TSS, SSS, and CVR. Risk factors of convulsion were male sex, SSS, and CVR. This is the largest nationwide report, to date, of the clinical characteristics of dAVFs treated by neuroendovascular therapy. CVR was a major risk factor of aggressive symptoms.

Entities:  

Mesh:

Year:  2013        PMID: 24390192      PMCID: PMC4508691     

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


Introduction

Intracranial dural arteriovenous fistulas (dAVFs) are rare. The crude detection rates of dAVFs were reported to be 0.29 and 0.51 per 1,00,000 adults per year in Japan and Finland, respectively.[1,2)] The frequencies or outcomes of the dAVFs were not reported in the English literature of the nationwide surveys. DAVFs have been treated with a variety of treatments, including surgeries, endovascular procedures, radiation therapies, and a combination of these treatments. Over the past several decades, there have been rapid technological developments in microcatheters and embolic materials in the fields of interventional neuroradiology. Combined with experience, these improvements have permitted the application of catheter-based interventions to various types of cerebrovascular disease, and the number of catheter interventions is increasing tremendously in Japan. Currently, most patients with dAVFs are also treated with endovascular procedures. In this context, a multicenter study group (Japanese Registry of Neuroendovascular Therapy [JR-NET] Study Group) was formed in 2005 to clarify the factors that had an impact on the results of treatment and to establish standardized treatment by catheter intervention and systems of educating operators. This survey consisted of two phases. The first phase was JR-NET, from January 2005 to December 2006, and the second phase was JR-NET2, from January 2007 to December 2009. The target of treatment modalities in JR-NET and JR-NET2 were all neuroendovascular procedures, including embolization of dAVFs. In 2011, the clinical data of 863 patients with dAVFs from JR-NET data was reported by Kuwayama et al. to clarify the current status of treatment in the Japanese literature.[1)] In the present study, we collected a considerable amount of clinical data related to neuroendovascular therapy for cranial dAVFs through the JR-NET2 investigation. We analyzed this data to document the clinical characteristics of dAVFs treated with neuroendovascular therapy in Japan.

Patients and Methods

JR-NET2

Patients were derived from the JR-NET2 database. This was a retrospective, multicenter, observational study that took place from January 2007 through December 2009 in 150 neurosurgical centers with 169 neuroendovascular therapy specialists in Japan. A total of 20,854 procedures were included in JR-NET2, which was the largest database of neuroendovascular therapy in Japan. This database included 1,520 procedures (7.29%) with dAVFs.

Patient population

We collected all data related to cranial dAVFs from the JR-NET2 database, and analyzed them. All patients were treated with trans-arterial embolization (TAE), trans-venous embolization (TVE), or both. One thousand five hundred and twenty procedures with dAVFs involved embolization. Some dAVFs were treated with multistage procedures, and the patients' background and the clinical manifestation were evaluated in the patients at the time of the first procedure (patient population). The number of procedures and patient population consisted of 1,520 procedures and 1,075 patients who had undergone or attempted endovascular procedures for dAVFs between January 2007 and December 2009.

Evaluation

The dataset of this registry included the following parameters: basic information (facilities, date of treatment, and scheduled or emergent procedures), patient background (age, gender), clinical data [mdified Rankin Scale (mRS) before and 30 days after procedure), complication data (procedure related or not, severity), parameters specific to dAVFs [location, existence of cortical venous reflux (CVR) and varix], and details of endovascular procedures (class of operator, involvement of advising doctor, anesthesia, treatment strategies, type of embolization, type of catheters and embolic materials, result of procedures, and technological success). The locations of dAVFs in this registration were categorized in the nine sites as shown in Table 1.
Table 1

Clinical and imaging characteristics of dural arteriovenous fistulas

VariableTotalCSTSSSSSCMSTentoriumACFSPSCCJMultipleOthersn.d.
Number of patients1075469359514031131010215714
Male sex (%)479 (45)120 (26)195 (54)39 (76)20 (50)21 (68)11 (84)7 (70)6 (60)13 (62)
Mean age in yrs ± SD65 ± 1367 ± 1366 ± 1160 ± 1762 ± 1059 ± 1465 ± 663 ± 1259 ± 1662 ± 16
SymptomsAggressive symptoms (%)251 (23)15 (3)151 (42)29 (57)4 (10)13 (42)4 (31)3 (30)5 (50)8 (38)
  Hemorrhage (%)129 (12)6 (1)74 (21)12 (24)2 (5)10 (32)4 (31)2 (20)4 (40)3 (14)
  Venous infarction (%)93 (9)7 (1)63 (18)10 (20)1 (3)3 (10)0 (0)1 (10)0 (0)4 (19)
  Convulsion (%)29 (3)2 (0.4)14 (4)7 (14)1 (3)0 (0)0 (0)0 (0)1 (10)1 (5)
Non-aggressive symptoms (%)677 (63)446 (95)145 (40)12 (24)33 (83)5 (16)2 (15)4 (40)3 (30)10 (48)
Asymptomatic (%)67 (6)4 (1)28 (8)7 (14)0 (0)7 (23)7 (54)2 (20)0 (0)0 (0)
CVRCVR w/varix (%)168 (16)38 (8)71 (20)10 (20)3 (8)15 (48)7 (54)4 (40)2 (20)3 (14)
CVR w/o varix (%)560 (52)218 (46)224 (62)37 (73)15 (38)11 (35)5 (38)6 (60)4 (40)13 (62)

ACF: anterior cranial fossa, CCJ: cranio-cervical junction, CMS: condylar-marginal sinus, CS: cavernous sinus, CVR: cortical venous reflux, n.d.: not described, SPS: superior petrosal sinus, SSS: superior sagittal sinus, TSS: transverse-sigmoid sinus, w: with, w/o: without, yrs: years.

In this report, we described the epidemiology, such as basic information, patient's background, clinical presentations, and imaging characteristics of each location. Furthermore, we analyzed the risk factors associated with hemorrhage presentation, venous infarction, and convulsion. We plan to give detailed reports separately regarding the details of endovascular procedures and endpoints, such as the mRS score of 0 to 2 at 30 days after treatment, technological success of treatments, and adverse events within 30 days after treatment.

Statistical Analysis

All calculations were performed using JMP 9 software (SAS Institute Inc., Cary, North Carolina, USA). Descriptive statistics were expressed as the means ± standard deviations (SDs). The univariate associations between each potential risk factor and the occurrence of hemorrhage presentation, venous infarction, and convulsion were assessed using Fisher's exact test for comparisons with a cell size less than 10 and Pearson's χ2 test for others. Results were presented as relative risk (RR) with 95% confidence intervals (CIs). After eliminating variables that were closely related to others, the potential risk factors with a probability value of less than 0.05 on univariate analysis were adopted as confounders in the multivariate logistic regression model for multivariate analysis to determine whether or not risk factors remained independently associated with the occurrence of hemorrhage presentation, venous infarction and convulsion. Results were presented as odds ratio (OR) estimates of RR with 95% CIs. Significance level was set at a p value of less than 0.05.

Results

Location of dAVFs and patient background

Of 1,075 patients, 45% were men and 55% were women. The mean age was 65 ± 13 years (Table 1). In terms of the location of dAVFs, the cavernous sinus (CS) was most frequent. The CS was involved in 469 patients (43.6%), transverse-sigmoid sinus (TSS) in 359 (33.4%), superior sagittal sinus (SSS) in 51 (4.7%), condylar-marginal sinus (CMS) in 40 (3.7%), tentorium in 31 (2.9%), anterior cranial fossa (ACF) in 13 (1.2%), superior petrosal sinus (SPS) in 10 (0.9%), cranio-cervical junction (CCJ) in 10 (0.9%), other locations in 57 (5.3%), unspecified locations in 14 (1.3%), and various locations for multiple lesions in 21 (2.0%). The proportion of men was higher than or equal to 50% for all locations except the CS (26%).

Clinical presentation and imaging characteristics

The clinical and imaging characteristics of dAVFs are summarized in Table 1. Two hundred and fifty-one patients (23%) presented with aggressive symptoms. One hundred and twenty-nine patients had intracranial hemorrhage, 93 patients had venous infarction, and 29 patients had convulsion. Six hundred and seventy-seven patients (63%) presented with non-aggressive symptoms. In these patients, 447 patients had ophthalmic symptoms (exophthalmos, chemosis, or ophthalmoplegia), 35 patients had headache, and 195 patients had pulsatile tinnitus or bruit. Sixty-seven patients (6%) were found incidentally, and the symptoms of 24 patients were unknown. One hundred and sixty-eight patients (16%) had dAVF with CVR with varix; 560 patients (52%) had dAVF with CVR without varix; and 320 patients (30%) had dAVF without CVR. Aggressive symptoms and CVR were more abundant in the TSS dAVFs (42% and 82%, respectively) than in the CS dAVFs (3% and 54%, respectively). The results of univariate and multivariate analysis of factors related to intracranial hemorrhage as a primary symptom are summarized in Table 2. The analysis revealed that TSS location (OR, 4.1, 95% CI, 2.5–6.8; p < 0.0001), SSS location (OR, 4.3, 95% CI, 1.6–9.6; p = 0.0004), tentorium location (OR, 5.8, 95% CI, 2.2–14.6; p = 0.0002), ACF location (OR, 4.1, 95% CI, 1.0–14.7; p = 0.0359), CCJ location (OR, 19.8, 95% CI, 3.8–110.2; p = 0.0004), CVR (OR, 17.5, 95% CI, 5.3–108.5; p < 0.0001), and varix (OR, 3.0, 95% CI, 1.9–4.6; p < 0.0001) were significantly associated with hemorrhagic presentation in patients with dAVFs.
Table 2

Hemorrhagic presentation in dural arteriovenous fistulas

VariableUnivariateMultivariate


RR95% CIP valueOR95% CIP value
Age older than 60 years0.90.6–1.30.6694
Age older than 70 years0.80.6–1.20.415
Male sex1.61.2–2.30.00331.20.8–1.80.5044
Cavernous sinus0.10.0–0.1< 0.0001
Transverse-sigmoid sinus2.71.9–3.7< 0.00014.12.5–6.8< 0.0001
Superior sagital sinus2.11.2–3.50.00964.31.6–9.60.0004
Condylar-marginal sinus0.40.1–1.60.2162
Tentorium2.91.7–4.90.00045.82.2–14.60.0002
Anterior cranial fossa2.61.1–5.90.0644.11.0–14.70.0359
Superior petrosal sinus1.60.5–5.70.3525
Cranio-cervical junction3.31.5–7.20.025219.83.8–110.20.0004
Multiple1.20.4–3.40.7355
Cortical venous reflux27.86.9–111.6< 0.000117.55.3–108.5< 0.0001
Varix3.92.8–5.3< 0.00013.01.9–4.6< 0.0001

CI: confidence interval, OR: odds ratio, RR: relative risk.

The results of univariate and multivariate analysis of factors related to venous infarction as a primary symptom are summarized in Table 3. The analysis revealed that age older than 60 years (OR, 3.0, 95% CI, 1.6–6.0; p = 0.0008), male sex (OR, 2.0, 95% CI, 1.2–3.2; p = 0.0059), TSS location (OR, 4.8, 95% CI, 2.8–8.4; p < 0.0001), SSS location (OR, 4.3, 95% CI, 1.7–10.0; p = 0.001), and CVR (OR, 14.9, 95% CI, 4.6–91.5; p = 0.0002) were significantly associated with venous infarction in patients with dAVFs.
Table 3

Venous infarction in dural arteriovenous fistulas

VariableUnivariateMultivariate


RR95% CIP valueOR95% CIP value
Age older than 60 years2.41.3–4.40.0023.01.6–6.00.0008
Age older than 70 years1.71.2–2.50.0055
Male sex2.21.4–3.20.00012.01.2–3.20.0059
Cavernous sinus0.10.04–0.2< 0.0001
Transverse-sigmoid sinus4.22.7–6.3< 0.00014.82.8–8.4< 0.0001
Superior sagital sinus2.41.3–4.40.00444.31.7–10.00.001
Condylar-marginal sinus0.30.04–2.00.2467
Tentorium1.10.4–3.40.7433
Anterior cranial fossa00.6196
Superior petrosal sinus1.10.2–7.30.6057
Cranio-cervical junction01
Multiple2.21.0–5.40.1071
Cortical venous reflux20.25.0–81.6< 0.000114.94.6–91.50.0002
Varix1.40.9–2.30.1297

CI: confidence interval, OR: odds ratio, RR: relative risk.

The results of univariate and multivariate analysis of factors related to convulsion as a primary symptom are summarized in Table 4. The analysis revealed that male sex (OR, 3.1, 95% CI, 1.4–8.1; p = 0.0113), SSS location (OR, 4.0, 95% CI, 1.5–9.8; p = 0.0037), and CVR (OR, 9.9, 95% CI, 2.1–178.2; p = 0.0252) were significantly associated with convulsion in patients with dAVFs.
Table 4

Convulsion in dural arteriovenous fistulas

VariableUnivariateMultivariate


RR95% CIP valueOR95% CIP value
Age older than 60 years0.70.3–1.40.2943
Age older than 70 years1.00.5–2.11
Male sex3.91.7–9.10.00093.11.4–8.10.0113
Cavernous sinus0.10.0–0.4< 0.0001
Transverse-sigmoid sinus1.90.9–3.80.0857
Superior sagital sinus6.42.9–14.2< 0.00014.01.5–9.80.0037
Condylar-marginal sinus0.90.1–6.61
Tentorium01
Anterior cranial fossa01
Superior petrosal sinus01
Cranio-cervical junction3.70.6–24.70.245
Multiple1.80.2–12.30.4475
Cortical venous reflux12.41.7–91.00.00049.92.1–178.20.0252
Varix2.00.9–4.40.1168

CI: confidence interval, OR: odds ratio, RR: relative risk.

Discussion

Two nationwide surveillances of dAVF or vascular malformation were previously published. The report from Scotland was mainly related to arteriovenous malformations and they included only 13 cases with dAVFs.[3)] Kuwayama et al.[1)] reported the characteristics and status of the treatment of each dAVF in Japan. They included 863 cases with dAVFs treated by endovascular procedures as well as by surgery, radiosurgery, and conservative management. There have been various single and multi-center reported series of dAVFs.[2,4–11)] Singh et al.[9)] reported the largest series, which included 402 patients with dAVFs. Here, we report the largest survey to date on the characteristics of each dAVF.

Location

Kuwayama et al.[1)] reported that CS was involved in 45.9% of patients, TSS in 26.7%, spinal cord in 5.9%, anterior condylar confluence in 5.0%, tentorium in 4.8%, SSS in 3.2%, CCJ in 2.4%, cranial vault in 2.4%, anterior cranial base in 2.1%, confluence of the sinus in 1.4%, and multiple locations in 1.4%. On the other hand, the previous largest series from a single center in California reported that CS was involved in 40.5% of patients, TSS in 30.8%, posterior fossa in 8.0%, superior petrosal sinus in 5.5%, SSS in 4.5%, marginal sinus in 4.2%, ethmoidal in 3.0%, middle cranial fossa in 2.2%, inferior petrosal sinus in 1.2%, and multiple locations in 15.9%. Previous series from Western countries[2,4–6,8,12)] reported that the most frequent location of dAVF was TSS, followed by CS. On the other hand, CS was reported as the most frequent location of dAVFs in Asian populations.[1,13,14)] Our data confirmed the tendency that CS location is more frequent than TSS location in Asia. Certain anatomic locations of dAVFs, such as the tentorium, ACF, and CCJ, are more amenable for surgery.[1,15–17)] We consider that this explained the low frequencies in tentorium, ACF, and CCJ locations in our survey, which had no dAVF data related to surgery, stereotactic radiation therapy, or conservative cases.

Clinical presentation

It is well known that a higher risk of intracranial hemorrhage and non-hemorrhagic neurological deficit is seen in dAVFs with CVR. We reviewed 12 reports related to the risk factors of intracranial hemorrhage and non-hemorrhagic neurological deficit in patients with dAVFs. The results are shown in Table 5.[4,7,9–12,14,18–22)] Recently, Singh et al.[9)] reported the largest series of dAVFs, in which cortical venous drainage, focal neurological deficits, posterior fossa location, male sex, and patients older than 50 years were found to be independently associated with hemorrhagic presentation; CVR has the highest odds ratio (OR, 10.5, 95% CI, 4.9–22.6; p < 0.001). Several major classifications of dAVFs have been developed to grade the risks of dAVFs, including those devised by Cognard et al.,[6)] Borden et al.,[23)] and Lalwani et al.[8)] In our reports, we confirmed the earlier findings that CVR is associated with the risk of intracranial hemorrhage and venous infarction, respectively. Furthermore, we revealed the fact that CVR is associated with the risk of convulsion, too.
Table 5

Review of literatures on risk factors for intracranial hemorrhage or aggressive symptoms in dural arteriovenous fistula

SeriesYearNo. of casesRisk factors
Malik et al.[20)]198410Leptomeningeal venous drainage, large variceal dilatation
Viñuela et al.[21)]198614Leptomeningeal venous drainage
Awad et al.[12)]199017Leptomeningeal venous drainage, venous dilatation, galenic drainage
Brown et al.[4)]199454Venous varix
Davies et al.[7)]1996102Leptomeningeal venous drainage, sinus occlusion, venous ectasia
Willinsky et al.[22)]1999130Pseudophlebitic pattern of venous drainage
Kim et al.[14)]200253Retrograde intracranial venous drainage
van Dijk et al.[11)]2002236Persistent cortical venous reflex
Lucas et al.[19)]200693Anterior fossa and tentorial location, leptomenigeal drainage, venous dilatation
Singh et al.[9)]2008402Male sex, age, posterior fossa location, cortical venous reflux
Söderman et al.[10)]200885Cortical venous reflux, prsentation with past hemorrhage
Bulters et al.[18)]201275Cortical venous reflux, venous ectasia
The tendency for dAVFs in some locations, such as the tentorium, ACF, SSS, and posterior fossa, to present more frequently with hemorrhage or aggressive symptoms, have been reported.[6,7,9,12)] In a previous Japanese survey, Kuwayama et al. reported that the incidence of aggressive symptoms (hemorrhage, venous infarction, elevated intracranial pressure, and convulsion) was 5.6% in CS, 60% in TSS, 67% in confluence, 82% in SSS, 17% in the anterior cranial base, 51% in tentorium, 19% in ACC, 86% in CCJ, and 52% in vault. We found that intracranial hemorrhage was more abundant in the TSS, SSS, tentorium, ACF, and CCJ locations. Except for the TSS location, our results were similar to those of previous reports. Additionally, we found that venous infarction was abundant in the TSS and SSS locations, and that convulsion was abundant in the SSS location. The dangerous symptoms of these locations are a function of their more dangerous venous anatomies. When major sinuses such as the TSS and SSS are involved in dAVFs with CVR, the influences of blocked venous outflow were greater than that for other sinuses or veins. We believe that this is why patients with dAVFs in the TSS or SSS locations developed more dangerous presentations. The reasons for the low risk of aggressive symptoms in the CS location are the low possession rate of CVR and the high rate of benign symptoms as heralds. We found that male sex was an independent risk factor for venous infarction and convulsion of dAVFs. In the present study, we demonstrated that CVR was more frequent in men than in women (72% and 64%, respectively), and that the proportion of men was higher than or equal to 50% for all locations except the CS. Previous studies also reported that men had dAVFs with CVR more often than women.[18,24,25)] We consider that this prevalence of CVR resulted in a higher risk of venous infarction and convulsion in male patients than in female patients.

Study limitations

The present study has some limitations. First, although the amount of data was large, there was no dAVF data related to surgery, radiosurgery, and conservative cases. Thus, our data did not accurately reflect the prevalence of dAVFs. Second, we could not determine if the data was from the same patient or if multiple procedures were done, so we considered the number of first procedures to be the number of patients. In the future, we need to accumulate all the data of each patient with dAVFs treated by endovascular procedures as well as by surgery, radiosurgery, and conservative management in Japan in order to conduct the definitive nation-wide study of epidemiology.

Conclusion

A total of 1,075 patients with dAVFs underwent 1,520 endovascular procedures between January 2007 and December 2009 in Japan. In terms of location of dAVFs, the CS was the most frequent, followed by TSS. CVR was the major risk factor of aggressive symptoms such as hemorrhagic presentation, venous infarction, and convulsion.
  24 in total

1.  Do leptomeningeal venous drainage and dysplastic venous dilation predict hemorrhage in dural arteriovenous fistula?

Authors:  César de Paula Lucas; José Guilherme Mendes Pereira Caldas; Mirto N Prandini
Journal:  Surg Neurol       Date:  2006

2.  The validity of classification for the clinical presentation of intracranial dural arteriovenous fistulas.

Authors:  M A Davies; K TerBrugge; R Willinsky; T Coyne; J Saleh; M C Wallace
Journal:  J Neurosurg       Date:  1996-11       Impact factor: 5.115

3.  Tortuous, engorged pial veins in intracranial dural arteriovenous fistulas: correlations with presentation, location, and MR findings in 122 patients.

Authors:  R Willinsky; M Goyal; K terBrugge; W Montanera
Journal:  AJNR Am J Neuroradiol       Date:  1999 Jun-Jul       Impact factor: 3.825

4.  Ethmoidal dural arteriovenous fistulae: an assessment of surgical and endovascular management.

Authors:  M T Lawton; J Chun; C B Wilson; V V Halbach
Journal:  Neurosurgery       Date:  1999-10       Impact factor: 4.654

5.  Intracranial dural arteriovenous malformations: factors predisposing to an aggressive neurological course.

Authors:  I A Awad; J R Little; W P Akarawi; J Ahl
Journal:  J Neurosurg       Date:  1990-06       Impact factor: 5.115

6.  Selective disconnection of cortical venous reflux as treatment for cranial dural arteriovenous fistulas.

Authors:  J Marc C van Dijk; Karel G TerBrugge; Robert A Willinsky; M Christopher Wallace
Journal:  J Neurosurg       Date:  2004-07       Impact factor: 5.115

7.  Dural arteriovenous malformations and intracranial hemorrhage.

Authors:  G M Malik; J E Pearce; J I Ausman; B Mehta
Journal:  Neurosurgery       Date:  1984-09       Impact factor: 4.654

8.  Intracranial dural arteriovenous fistulae: angiographic predictors of intracranial hemorrhage and clinical outcome in nonsurgical patients.

Authors:  R D Brown; D O Wiebers; D A Nichols
Journal:  J Neurosurg       Date:  1994-10       Impact factor: 5.115

9.  A proposed classification for spinal and cranial dural arteriovenous fistulous malformations and implications for treatment.

Authors:  J A Borden; J K Wu; W A Shucart
Journal:  J Neurosurg       Date:  1995-02       Impact factor: 5.115

10.  Unusual clinical manifestations of dural arteriovenous malformations.

Authors:  F Viñuela; A J Fox; D M Pelz; C G Drake
Journal:  J Neurosurg       Date:  1986-04       Impact factor: 5.115

View more
  17 in total

1.  Changing Clinical and Therapeutic Trends in Tentorial Dural Arteriovenous Fistulas: A Systematic Review.

Authors:  D Cannizzaro; W Brinjikji; S Rammos; M H Murad; G Lanzino
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-27       Impact factor: 3.825

2.  Endovascular treatment of dural arteriovenous fistulas with sinus drainage: Do we really need to protect the sinus?

Authors:  Hans Kortman; Issam Boukrab; Menno Sluzewski; Willem Jan van Rooij; Jo Pp Peluso; Charles Majoie
Journal:  Interv Neuroradiol       Date:  2019-02-04       Impact factor: 1.610

3.  Accelerated Time-Resolved Contrast-Enhanced Magnetic Resonance Angiography of Dural Arteriovenous Fistulas Using Highly Constrained Reconstruction of Sparse Cerebrovascular Data Sets.

Authors:  Zachary Clark; Kevin M Johnson; Yijing Wu; Myriam Edjlali; Charles Mistretta; Oliver Wieben; Patrick Turski
Journal:  Invest Radiol       Date:  2016-06       Impact factor: 6.016

4.  Usefulness of end-diastolic ratio in carotid ultrasonography for the screening of dural arteriovenous fistula: a case series.

Authors:  Toshiaki Goda; Junya Kobayashi; Nobuyuki Ohara; Takeshi Ikegami; Kotaro Watanabe; Daisuke Takahashi
Journal:  J Med Ultrason (2001)       Date:  2017-03-14       Impact factor: 1.314

Review 5.  Endovascular Management of Intracranial Dural AVFs: Principles.

Authors:  K D Bhatia; H Lee; H Kortman; J Klostranec; W Guest; T Wälchli; I Radovanovic; T Krings; V M Pereira
Journal:  AJNR Am J Neuroradiol       Date:  2021-10-21       Impact factor: 3.825

6.  UPDATE ON MANAGEMENT OF DURAL ARTERIOVENOUS FISTULAS.

Authors:  Mohammed A Azab; Emma R Dioso; Matthew C Findlay; Jayson Nelson; Cameron A Rawanduzy; Philip Johansen; Brandon Lucke-Wold
Journal:  J Rare Dis Orphan Drugs       Date:  2022-06-07

7.  Dural Arteriovenous Fistula Mimicking a Brain Tumor on Methionine-positron Emission Tomography: A Case Report.

Authors:  Taketo Hanyu; Masahiro Nishihori; Takashi Izumi; Kazuya Motomura; Fumiharu Ohka; Shunsaku Goto; Yoshio Araki; Kinya Yokoyama; Kenji Uda; Ryuta Saito
Journal:  NMC Case Rep J       Date:  2022-09-15

8.  A hemorrhagic complication after Onyx embolization of a tentorial dural arteriovenous fistula: A caution about subdural extension with pial arterial supply.

Authors:  Kenichi Sato; Yasushi Matsumoto; Hidenori Endo; Teiji Tominaga
Journal:  Interv Neuroradiol       Date:  2017-01-01       Impact factor: 1.610

9.  Artery of Davidoff and Schechter Supply in Dural Arteriovenous Fistulas.

Authors:  K D Bhatia; H Kortman; T Wälchli; I Radovanovic; V M Pereira; T Krings
Journal:  AJNR Am J Neuroradiol       Date:  2020-01-23       Impact factor: 3.825

10.  Intraoperative cone-beam computed tomography contributes to avoiding hypoglossal nerve palsy during transvenous embolization for dural arteriovenous fistula of the anterior condylar confluence.

Authors:  Akitake Okamura; Mitsuo Nakaoka; Naohiko Ohbayashi; Kaita Yahara; Shinya Nabika
Journal:  Interv Neuroradiol       Date:  2016-06-10       Impact factor: 1.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.